One possible explanation for such an improvement in hepatic steatosis and inflammation by canagliflozin is the inhibition of de novo lipogenesis, since the present study showed that expression of FAS, a gene involved in lipogenesis [15], was significantly lower in the canagliflozin group than in the vehicle group. The gene discussed is FAS; the disease is fatty liver disease.